CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 308 enrolled
Drug / intervention
Tritanrix™-HepB +5 morebiological
Likely dose
Not stated in record
Key inclusion· 3
  • Administration of one dose of hepatitis B vaccine at birth
  • Male or female infant between 11 and 17 weeks of age at first DTPw vaccination
  • Free of obvious health problems by medical history and clinical examination
Key exclusion· 5
  • Use of any investigational or non-registered product within 30 days before first study vaccine dose or planned use during study
  • Chronic administration of immunosuppressants or other immune-modifying drugs since birth
  • Planned or actual non-protocol vaccine administration within 30 days before first dose or during study, except oral polio vaccine
  • Any confirmed or suspected immunosuppressive or immunodeficient condition

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00158756
NCT00158756Phase 3Completed

A Phase III, Partially Blind, Randomized Study to Evaluate the Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Tritanrix™-HepB and GSK Biologicals Kft's DTPw-HBV Vaccines as Compared to Concomitant Administration of Commonwealth Serum Laboratory's (CSL's) DTPw (Triple Antigen™) and GSK Biologicals' HBV (Engerix™-B), When Co-administered With GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, to Healthy Infants at 3, 4½ and 6 Months of Age, After a Birth Dose of Hepatitis B Vaccine.

GlaxoSmithKline·interventional·Posted Sep 12, 2005·Updated Jun 6, 2018

In Brief

A Phase 3 clinical trial evaluating Tritanrix™-HepB, Rotarix™, and 4 other interventions for Hepatitis B. Completed, enrolled 308 participants across 9 sites.

Detailed Summary

To compare the two formulations of GSK Biologicals' DTPw-HBV vaccine to concomitant administration of CSL's DTPw vaccine and GSK Biologicals' HBV with respect to the antibody response to the diphtheria antigen after a three-dose primary vaccination course.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 12, 2005
Enrollment StartSep 12, 2005
Primary CompletionNov 1, 2006
Study CompletionNov 23, 2006
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 20.8 years ago

Interventions

Tritanrix™-HepBbiological

GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.

Rotarix™biological

GSK Biologicals' live attenuated human rotavirus vaccine

Zilbrix™biological

GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine

Triple Antigen™biological

Commonwealth Serum Laboratory's (CSL's) combined diphtheria-tetanus-whole cell B. pertussis vaccine.

Engerix™-Bbiological

GSK Biologicals' hepatitis B vaccine

Placebodrug

Placebo for the Rotarix™ vaccine